Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

BACKGROUND: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindström, Ulf, Di Giuseppe, Daniela, Delcoigne, Bénédicte, Glintborg, Bente, Möller, Burkhard, Ciurea, Adrian, Pombo-Suarez, Manuel, Sanchez-Piedra, Carlos, Eklund, Kari, Relas, Heikki, Gudbjornsson, Bjorn, Love, Thorvardur Jon, Jones, Gareth T, Codreanu, Catalin, Ionescu, Ruxandra, Nekvindova, Lucie, Závada, Jakub, Atas, Nuh, Yolbas, Servet, Fagerli, Karen Minde, Michelsen, Brigitte, Rotar, Žiga, Tomšič, Matija, Iannone, Florenzo, Santos, Maria Jose, Avila-Ribeiro, Pedro, Ørnbjerg, Lykke Midtbøll, Østergaard, Mikkel, Jacobsson, Lennart TH, Askling, Johan, Nissen, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522446/
https://www.ncbi.nlm.nih.gov/pubmed/34083206
http://dx.doi.org/10.1136/annrheumdis-2021-220097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522446/
https://www.ncbi.nlm.nih.gov/pubmed/34083206
http://dx.doi.org/10.1136/annrheumdis-2021-220097

Ejemplares similares